Fc-mediated antibody effector functions during respiratory syncytial virus infection and disease

EA Van Erp, W Luytjes, G Ferwerda… - Frontiers in …, 2019 - frontiersin.org
Respiratory syncytial virus (RSV) is a major cause of severe lower respiratory tract infections
and hospitalization in infants under 1 year of age and there is currently no market-approved …

Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children

L Garegnani, L Styrmisdottir… - Cochrane Database …, 2021 - cochranelibrary.com
Background Respiratory viruses are the leading cause of lower respiratory tract infection
(LRTI) and hospitalisation in infants and young children. Respiratory syncytial virus (RSV) is …

Evidence-based clinical guidelines for immigrants and refugees

K Pottie, C Greenaway, J Feightner, V Welch… - Cmaj, 2011 - Can Med Assoc
Health: Deborah Assayag, Elizabeth Barnett, Jennifer Blake, Beverly Brockest, Giovani
Burgos, Glenn Campbell, Andrea Chambers, Angie Chan, Maryann Cheetham, Walter …

The estimated prevalence and incidence of late stage age related macular degeneration in the UK

CG Owen, Z Jarrar, R Wormald, DG Cook… - British Journal of …, 2012 - bjo.bmj.com
Background UK estimates of age related macular degeneration (AMD) occurrence vary.
Aims To estimate prevalence, number and incidence of AMD by type in the UK population …

Bronchiolitis: recent evidence on diagnosis and management

JJ Zorc, CB Hall - Pediatrics, 2010 - publications.aap.org
Viral bronchiolitis is a leading cause of acute illness and hospitalization of young children.
Research into the variation in treatment and outcomes for bronchiolitis across different …

Risk factors for hospital admission with RSV bronchiolitis in England: a population-based birth cohort study

J Murray, A Bottle, M Sharland, N Modi, P Aylin… - PloS one, 2014 - journals.plos.org
Objective To examine the timing and duration of RSV bronchiolitis hospital admission
among term and preterm infants in England and to identify risk factors for bronchiolitis …

Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children

T Andabaka, JW Nickerson… - … ‐Based Child Health …, 2013 - Wiley Online Library
Background Respiratory syncytial virus (RSV) is one of the most important viral pathogens
causing acute respiratory infections, resulting in about 3.4 million hospitalisations annually …

Minimal Elements Required for the Formation of Respiratory Syncytial Virus Cytoplasmic Inclusion Bodies In Vivo and In Vitro

M Galloux, J Risso-Ballester, CA Richard, J Fix… - MBio, 2020 - Am Soc Microbiol
Infection of host cells by the respiratory syncytial virus (RSV) is characterized by the
formation of spherical cytoplasmic inclusion bodies (IBs). These structures, which …

Cost-effectiveness of palivizumab for respiratory syncytial virus: a systematic review

S Mac, A Sumner, S Duchesne-Belanger, R Stirling… - …, 2019 - publications.aap.org
OBJECTIVE: To systematically review the cost-effectiveness of palivizumab prophylaxis
compared with no prophylaxis in infants< 24 months of age. DATA SOURCES: Medline …

Evaluating the next generation of RSV intervention strategies: a mathematical modelling study and cost-effectiveness analysis

D Hodgson, R Pebody, J Panovska-Griffiths… - BMC medicine, 2020 - Springer
Background With a suite of promising new RSV prophylactics on the horizon, including long-
acting monoclonal antibodies and new vaccines, it is likely that one or more of these will …